Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Dec;10(4):232-8.
doi: 10.1016/j.clgc.2012.05.001. Epub 2012 Jun 12.

Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer

Robert J Amato  1 , George Wilding, Glenn Bubley, John Loewy, Frank Haluska, Mitchell E Gross
Affiliations
Clinical Trial

Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer

Robert J Amato et al. Clin Genitourin Cancer. 2012 Dec.

Abstract

Background: Few options are available after taxane-based therapy in men with CRPC. Genetic alterations involving the mTOR pathway have been associated with CRPC development, raising the hypothesis that blocking mTOR signaling may be an effective targeted approach to treatment.

Patients and methods: In this open-label phase II study, the mTOR inhibitor Ridaforolimus was administered at a dose of 50 mg intravenous once weekly to 38 patients with taxane-treated CRPC. The primary end point was best overall response according to modified Response Evaluation Criteria in Solid Tumors guidelines. Serum prostate-specific antigen levels were prospectively monitored as a biomarker for cancer activity.

Results: No objective responses were observed, but 18 patients (47.4%) had stable disease as their best response. Based on progression-free survival analysis, median time to progression with Ridaforolimus was 28 days (95% confidence interval, 27-29). Eight patients (21.1%) had stable disease as their best overall prostate-specific antigen response. The median number of days from first to last dose was 109.5 days (range, 1-442 days). Ridaforolimus was generally well tolerated, with a safety profile similar to that observed in patients with advanced malignancies. The most common side effects were typically mild or moderate in severity.

Conclusions: Ridaforolimus was generally well tolerated. Treatment did not produce objective responses, but stable disease was observed in some patients with taxane-treated CRPC. Alternative treatment regimens, such as combination therapy with a taxane or in a maintenance treatment paradigm, should be considered for further evaluation in this patient population.

Trial registration: ClinicalTrials.gov NCT00110188.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient Disposition
Figure 2
Figure 2
Progression-Free Survival of Taxane-Treated CRPC Patients Treated With Ridaforolimus. Kaplan-Meier Analysis of 38 Patients Treated With Ridaforolimus Showed a Median Time to Progression of 28 Days (95% CI, 27–29)
Figure 3
Figure 3
Percentage Change in PSA from Baseline to 12 Weeks,a or the Maximum Decline in PSA That Occurred at Any Point After Treatment for Each Patient
See this image and copyright information in PMC

References

    1. American Cancer Society . Cancer Facts and Figures 2010. American Cancer Society; Atlanta: 2010.
    1. Surveillance Epidemiology and End Results Program [May 29, 2012];SEER Stat Fact Sheets: Prostate. Available at: http://seer.cancer.gov/statfacts/html/prost.html.
    1. National Comprehensive Cancer Network [May 29, 2012];NCCN clinical practice guidelines in oncology: prostate cancer. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#prostate.
    1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. - PubMed
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. - PubMed

Publication types

MeSH terms

Associated data